Literature DB >> 10362840

Structural features in heparin that interact with VEGF165 and modulate its biological activity.

K Ono1, H Hattori, S Takeshita, A Kurita, M Ishihara.   

Abstract

The 165 amino acid form of vascular endothelial growth factor (VEGF165) is a heparin-binding growth factor with mitogenic activity for vascular endothelial cells. We examined activities of various heparin derivatives toward their interactions with VEGF165 using an enzyme-linked immunosorbent assay and elucidated the structural features in heparin for the interactions. Native heparin interacted with VEGF165, whereas N-desulfated, N-acetylated (N-DS, N-Ac-) heparin, and 6-O-desulfated (6-O-DS-) heparin did not. The 2-O-desulfated (2-O-DS-) heparin retained the ability for the interaction with VEGF165. In contrast, the 2-O-DS-heparin exhibited no ability for the interaction with FGF-2 and HGF. Thus, structural requirements in heparin for the specific interaction with VEGF165 are distinct from those with FGF-2 and HGF which require a high content of 2-O-sulfate groups. In a cell proliferation assay, native heparin and 2-O-DS-heparin exhibited inhibitory abilities for VEGF165-induced proliferation of human umbilical vein endothelial cells (HUVECs) with their high concentrations (more than 64 microg/ml), while only native heparin could enhance the proliferation of the chlorate-treated cells. These results suggested that a high content of 2-O-sulfate groups is not required for the specific interaction with VEGF165alone, although it is essential for the mitogenic activity of the growth factor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362840     DOI: 10.1093/glycob/9.7.705

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  33 in total

1.  Synergistic Binding of Vascular Endothelial Growth Factor-A and Its Receptors to Heparin Selectively Modulates Complex Affinity.

Authors:  Madelane Teran; Matthew A Nugent
Journal:  J Biol Chem       Date:  2015-05-15       Impact factor: 5.157

2.  Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity.

Authors:  Errol Wijelath; Mayumi Namekata; Jacqueline Murray; Mai Furuyashiki; Siyuan Zhang; Daniel Coan; Masahiro Wakao; Robert B Harris; Yasuo Suda; Lianchun Wang; Michael Sobel
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

3.  Extended N-sulfated domains reside at the nonreducing end of heparan sulfate chains.

Authors:  Gregory O Staples; Xiaofeng Shi; Joseph Zaia
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

4.  Lymphatic endothelial heparan sulfate deficiency results in altered growth responses to vascular endothelial growth factor-C (VEGF-C).

Authors:  Xin Yin; Scott C Johns; Roger Lawrence; Ding Xu; Krisanavane Reddi; Joseph R Bishop; Judith A Varner; Mark M Fuster
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

5.  Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides.

Authors:  Wenjing Zhao; Scott A McCallum; Zhongping Xiao; Fuming Zhang; Robert J Linhardt
Journal:  Biosci Rep       Date:  2012-02       Impact factor: 3.840

6.  Multifunctional silk-heparin biomaterials for vascular tissue engineering applications.

Authors:  F Philipp Seib; Manuela Herklotz; Kelly A Burke; Manfred F Maitz; Carsten Werner; David L Kaplan
Journal:  Biomaterials       Date:  2013-10-04       Impact factor: 12.479

7.  Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier.

Authors:  Yasutaka Mori; Shingo Nakamura; Satoko Kishimoto; Mitsuyuki Kawakami; Satoshi Suzuki; Takemi Matsui; Masayuki Ishihara
Journal:  Int J Nanomedicine       Date:  2010-04-07

8.  Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate.

Authors:  Koji M Nishiguchi; Keiko Kataoka; Shu Kachi; Keiichi Komeima; Hiroko Terasaki
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

9.  Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells.

Authors:  Arivalagan Muthusamy; Carlton R Cooper; Ronald R Gomes
Journal:  BMC Biochem       Date:  2010-11-03       Impact factor: 4.059

10.  Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis.

Authors:  Jason J Zoeller; John M Whitelock; Renato V Iozzo
Journal:  Matrix Biol       Date:  2009-05-05       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.